Glucophage's Glory comes to an end...
All too soon after losing its patents on paclitaxel (Taxol), the $1.7 billion breast cancer drug, Bristol-Myers Squibb may be in for another battering. This time its metformin (Glucophage), the company's $1.3 billion oral diabetes drug, which holds 35% share of the US oral diabetes market, has been vulnerable to generic attack since September.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."